



## Abivax publishes a prospectus in the context of its capital increase and bonds offering

July 23, 2021

**PARIS, FRANCE, July 23, 2021 – 9:00 p.m. (CEST)** – Abivax (Euronext Paris: FR0012333284 – ABVX) (the “Company”), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today announces the availability of an amendment to its 2021 Universal Registration Document filed with the French *Autorité des marchés financiers* (“AMF”) on April 30, 2021 under number D.20-0483 and of a listing prospectus approved by the AMF under number 21-345 on July 23, 2021, in the context of its reserved oversubscribed capital increase of approximately EUR 60M and its issuance of senior, unsecured bonds convertible into new shares and/or exchangeable for existing shares (*obligations convertibles échangeables en actions nouvelles ou existantes* - OCEANE) maturing in July 30, 2026 in aggregate principal amount of EUR 25M.

The prospectus is composed of:

- the 2021 Universal Registration Document filed with the AMF on April 30, 2021 under number D.20-0483;
- the amendment of the 2021 Universal Registration Document filed with the AMF on July 23, 2021 under number 21-0412-A01;
- a securities note (*note d’opération*); and
- the summary of the prospectus.

These documents are available on the websites of the Company ([www.abivax.com](http://www.abivax.com)) and/or on the website of the AMF ([www.amf-france.org](http://www.amf-france.org)).

\*\*\*\*\*

### About Abivax ([www.abivax.com](http://www.abivax.com))

Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at [www.abivax.com](http://www.abivax.com). Follow us on Twitter @ABIVAX\_.

### Contacts

**Abivax  
Communications**  
Regina Jehle  
[regina.jehle@abivax.com](mailto:regina.jehle@abivax.com)  
+33 6 24 50 69 63

**Investors  
LifeSci Advisors**  
Chris Maggos  
[thomasdeclimens@dgm-conseil.fr](mailto:thomasdeclimens@dgm-conseil.fr)  
+33 6 14 50 15 84

**Press Relations & Investors Europe  
MC Services AG**  
Anne Hennecke  
[chris@lifesciadvisors.com](mailto:chris@lifesciadvisors.com)  
+41 79 367 6254

**Public Relations France  
Actifin**  
Ghislaine Gasparetto  
[anne.hennecke@mc-services.eu](mailto:anne.hennecke@mc-services.eu)  
+49 211 529 252 22

**Public Relations France  
DGM Conseil**  
Thomas Roborel de Climens  
[ggasparetto@actifin.fr](mailto:ggasparetto@actifin.fr)  
+33 1 56 88 11 22

**Public Relations USA  
Rooney Partners LLC**  
Marion Janic  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)  
+1 212 223 4017

### DISCLAIMER

This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction, in particular in France. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgement. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.